| 1 |
NCT02959801 |
Recruiting |
Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis |
|
- Procedure: Percutaneous mechanical thrombectomy
|
Interventional |
Phase 4 |
- Beijing Tsinghua Chang Gung Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- post-thrombotic syndrome
- complication
|
50 |
All |
18 Years to 25 Years (Adult) |
NCT02959801 |
12015C1038 |
|
January 2016 |
December 2017 |
December 2017 |
November 9, 2016 |
November 9, 2016 |
|
- Beijing Tsinghua Chang Gung Hospital
Beijing, Beijing, China
|
| 2 |
NCT03178864 |
Not yet recruiting |
Study of Rivaroxaban for CeREbral Venous Thrombosis |
- Cerebral Venous Thrombosis
|
- Drug: Rivaroxaban
- Drug: Standard of care
|
Interventional |
Phase 2 |
- University of British Columbia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Composite rate of all-cause mortality, symptomatic intracranial bleeding, major extracranial bleeding
- All-cause mortality
- Symptomatic intracranial bleeding
- (and 10 more...)
|
384 |
All |
18 Years and older (Adult, Senior) |
NCT03178864 |
H17-00440 |
SECRET |
January 2018 |
June 2020 |
June 2020 |
June 7, 2017 |
October 27, 2017 |
|
|
| 3 |
NCT03033966 |
Completed |
Evaluation of Cerebral Oxygenation and Hemodynamics in Patients With Cerebral Venous Thrombosis |
- Cerebral Venous Thrombosis
|
- Device: NIRS based Cerebral Oximetry
|
Observational |
|
- Dhritiman Chakrabarti
- National Institute of Mental Health and Neuro Sciences, India
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Ipsilateral Regional Cerebral Oxygen Saturation
- Contralateral Regional Cerebral Oxygen Saturation
- Systolic Blood Pressure
- (and 3 more...)
|
17 |
All |
16 Years to 65 Years (Child, Adult) |
NCT03033966 |
Item No.6.04, Neurosciences |
|
February 10, 2016 |
June 30, 2016 |
June 30, 2016 |
January 27, 2017 |
January 27, 2017 |
|
- NIMHANS
Bangalore City, Karnataka, India
|
| 4 |
NCT02013635 |
Completed |
Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Clinical and Radiological Correlations |
- Cerebral Venous Thrombosis
|
|
Observational |
|
- University Hospital, Rouen
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Evolution of thrombin generation parameters
- Evolution of D Dimers concentration
- Evolution of thrombin generation parameters after end of treatment
- (and 3 more...)
|
232 |
All |
16 Years and older (Child, Adult, Senior) |
NCT02013635 |
2010/087/HP |
PHRC-TVC |
July 2011 |
September 2016 |
September 2016 |
December 17, 2013 |
November 10, 2016 |
|
- Chu Amiens
Amiens, France - Chu D' Angers
Angers, France - Ch Victor Dupouy
Argenteuil, France - (and 33 more...)
|
| 5 |
NCT02414802 |
Enrolling by invitation |
Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis |
|
- Device: a manual spiral thrombus broken suction device
- Procedure: catheter-directed thrombolysis
- Drug: low-molecular-weight heparin calcium
- Drug: urokinase
|
Interventional |
Not Applicable |
- Xuzhou Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- patency of lower extremity deep venous
- technical success rate
- thrombus removal rate
- (and 3 more...)
|
40 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02414802 |
BL2014030 |
|
December 2014 |
December 2017 |
December 2017 |
April 13, 2015 |
January 18, 2017 |
|
- Department of Interventional Radiology and Vascular Surgery, the Affiliated Hospital of Xuzhou Medical College
Xuzhou, Jiangsu, China
|
| 6 |
NCT03191305 |
Not yet recruiting |
Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis |
- Cerebral Venous Thrombosis
|
- Drug: Coumadin
- Drug: Rivoroxaban
|
Interventional |
Not Applicable |
- Foundation University Islamabad
- Shaheed Zulfiqar Ali Bhutto Medical University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Health Services Research
|
- Hemorrhage or Recurrent CVT based on repeat MRI.
- Cost
|
50 |
All |
13 Years to 50 Years (Child, Adult) |
NCT03191305 |
FUI/CTR/2017/2 |
CVT |
August 2017 |
September 2018 |
September 2018 |
June 19, 2017 |
June 19, 2017 |
|
|
| 7 |
NCT03217448 |
Recruiting |
The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis |
- Cerebral Venous Thrombosis
|
- Drug: Dabigatran etexilate
- Drug: Warfarin
|
Interventional |
Phase 3 |
- Capital Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The incidence of recanalized cerebral veins after 6 months
- Number of subjects with venous thrombosis events
- The change of optic disc edema grade and lumbar puncture pressure after 6 months
- (and 4 more...)
|
80 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03217448 |
DE-CVT |
|
October 30, 2017 |
January 2019 |
January 2019 |
July 14, 2017 |
November 22, 2017 |
|
- Xuanwu Hospital Capital Medical University
Beijing, China
|
| 8 |
NCT01474902 |
Withdrawn |
Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery |
- Asymptotic Venous Thrombosis
|
|
Interventional |
Phase 3 |
- The Hospital for Sick Children
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Net therapeutic benefit of enoxaparin
- Rate of objective clot size progression (or regression)
- Frequency and Risk Factors for conversion from asymptomatic to symptomatic thromboembolism
- (and 3 more...)
|
0 |
All |
up to 18 Years (Child, Adult) |
NCT01474902 |
1000022022 |
|
August 2011 |
August 2015 |
August 2015 |
November 18, 2011 |
August 27, 2013 |
|
- The Hospital for Sick Children
Toronto, Ontario, Canada
|
| 9 |
NCT01805544 |
Completed |
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication |
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
|
Observational |
|
- Bayer
- Janssen Research & Development, LLC
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change of the Anti Clot Treatment Scale (ACTS) score at 3 months compared with baseline score
- Change of ACTS score after 1 and 6 months of treatment
- Continuation rate at 1, 3 and 6 months
- (and 3 more...)
|
113 |
All |
18 Years and older (Adult, Senior) |
NCT01805544 |
16409
XA1214FR |
SATORI |
May 2013 |
April 2015 |
June 2015 |
March 6, 2013 |
January 23, 2017 |
|
|
| 10 |
NCT01684423 |
Completed
Has Results |
Oral Rivaroxaban in Children With Venous Thrombosis |
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
- Drug: Active comparator
- Drug: Rivaroxaban (BAY59-7939) suspension
|
Interventional |
Phase 2 |
- Bayer
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Subjects With Major and Clinically Relevant Non-Major Bleeding Events
- Number of Subjects With Symptomatic Recurrent Venous Thromboembolism
- Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden
- (and 4 more...)
|
64 |
All |
6 Years to 17 Years (Child) |
NCT01684423 |
14373
2011-004539-30 |
EINSTEINJunior |
February 19, 2013 |
September 1, 2016 |
September 1, 2016 |
September 13, 2012 |
September 21, 2017 |
September 21, 2017 |
- Little Rock, Arkansas, United States
- Los Angeles, California, United States
- Orange, California, United States
- (and 56 more...)
|
| 11 |
NCT00924859 |
Recruiting |
The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis (CVT) |
- Cerebral Venous Thrombosis
|
|
Observational |
|
- University Hospital Inselspital, Berne
- Schweizerische Herzstiftung
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- The overall diagnostic accuracy of FXIII-AP an D-dimer to exclude CVT in patients with clinical suspicion of CVT
- The overall frequency of CVT in patients with clinical suspicion of CVT
- The overall frequency of other diseases in patients with clinical suspicion of CVT
- The site of involved veins and sinus in patients with CVT
|
300 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT00924859 |
112/09 |
|
September 2009 |
December 31, 2017 |
December 31, 2017 |
June 19, 2009 |
September 28, 2017 |
|
- Department of Neurology, Academic Medical Centre, University of Amsterdam
Amsterdam, Netherlands - Dep. of Neurology, Bern University Hospital
Bern, Switzerland
|
| 12 |
NCT02744833 |
Completed |
Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT) |
|
- Drug: GMI-1271
- Drug: Enoxaparin Sodium (Lovenox®)
|
Interventional |
Phase 1
Phase 2 |
- GlycoMimetics Incorporated
- University of Michigan
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the safety and tolerability of GMI-1271 in patients with calf-level DVT by assessment with vital signs, standard laboratory blood tests, electrocardiogram, and adverse event evaluation.
- To evaluate the effects of GMI-1271 on thrombus resolution or stabilization as measured by Doppler ultrasound
- To evaluate the effects of GMI-1271 on the incidence of bleeding time
- (and 2 more...)
|
16 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02744833 |
GMI-1271-220 |
|
July 2016 |
November 2016 |
November 2016 |
April 20, 2016 |
February 28, 2018 |
|
- University of Michigan
Ann Arbor, Michigan, United States
|
| 13 |
NCT02704598 |
Unknown † |
Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs. |
|
- Drug: Rivaroxaban
- Drug: Warfarin
|
Interventional |
Not Applicable |
- Hospital do Servidor Publico Estadual
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Recanalization rate of deep venous thrombosis in lower limbs of 150 patients.
- Clinical Signs and Symptoms in 150 patients..
|
150 |
All |
21 Years to 79 Years (Adult, Senior) |
NCT02704598 |
123456 |
DVT |
October 2014 |
January 2017 |
January 2018 |
March 10, 2016 |
March 10, 2016 |
|
- Hospital do Servidor Público Estadual de São Paulo
São Paulo, SP, Brazil
|
| 14 |
NCT00808626 |
Withdrawn |
Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis |
|
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Establish the proof of concept that 99mTc-rBitistatin enables imaging of peripheral venous thrombi
- Continue to evaluate the safety of 99mTc-rBitistatin administered intravenously
|
0 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00808626 |
11556 |
|
December 2008 |
March 2017 |
March 2017 |
December 16, 2008 |
May 4, 2015 |
|
- Temple University Hospital
Philadelphia, Pennsylvania, United States
|
| 15 |
NCT03428711 |
Recruiting |
Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis |
- Superficial Venous Thrombosis of Leg, Secondary Prevention
|
- Drug: Mesoglycan Oral Tablet
- Drug: Placebo Oral Tablet
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Cumulative thrombosis recurrence
- Cumulative thrombosis recurrence with distal
- Symptoms
- Quality of Life
|
650 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03428711 |
METRO |
|
March 26, 2018 |
March 2022 |
September 2022 |
February 12, 2018 |
April 6, 2018 |
|
- Giuseppe Camporese
Padova, Italy
|
| 16 |
NCT00311090 |
Completed |
Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs |
|
- Drug: Idrabiotaparinux sodium
- Drug: Idraparinux sodium
- Drug: Avidin
- Drug: Placebo (for Avidin)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Bioequipotency sub-study: idrabiotaparinux/idraparinux ratio for pharmacodynamic exposure parameters
- Avidin neutralizing effect substudy: decrease in anti-Xa activity between the start and end of the avidin infusion
- Pharmacokinetic profile: idrabiotaparinux and idraparinux plasma concentrations
- (and 2 more...)
|
757 |
All |
18 Years and older (Adult, Senior) |
NCT00311090 |
EFC5945
2005-005326-30 |
EQUINOX |
April 2006 |
January 2008 |
January 2008 |
April 5, 2006 |
March 21, 2016 |
|
- Sanofi-Aventis
Bridgewater, New Jersey, United States - Sanofi-Aventis
Buenos Aires, Argentina - Sanofi-Aventis
Macquarie Park, Australia - (and 17 more...)
|
| 17 |
NCT00178789 |
Completed |
Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis |
|
|
Observational |
|
- The University of Texas Health Science Center, Houston
|
Other |
- Allocation: Random Sample
- Primary Purpose: Screening
- Time Perspective: Cross-Sectional
- Time Perspective: Prospective
|
|
51 |
All |
18 Years and older (Adult, Senior) |
NCT00178789 |
HSC-MS-05-0011 |
|
September 2005 |
|
May 2007 |
September 15, 2005 |
May 23, 2007 |
|
- Memorial Hermann Hospital Emergency Department
Houston, Texas, United States
|
| 18 |
NCT00628576 |
Completed |
Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities |
|
- Drug: unfractionated heparin
- Drug: Tinzaparin (Leo)
|
Interventional |
Phase 3 |
- Aalborg Universitetshospital
- Aalborg University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical evaluation of chronic venous insufficiency (CVI) - (Postthrombotic Syndrome) based on internationally accepted criteria.
|
99 |
All |
18 Years and older (Adult, Senior) |
NCT00628576 |
VN 2003/15 (2-16-4 - 0001- 03) |
|
October 1993 |
June 2004 |
June 2004 |
March 5, 2008 |
March 5, 2008 |
|
- Dept. of Haematology; Aalborg Hospital
Aalborg, Region Nordjylland, Denmark
|
| 19 |
NCT01325779 |
Withdrawn |
Comparison of Subcutaneous Heparin and Enoxaparin for Deep Venous Thrombosis (DVT) Prophylaxis in Surgical Intensive Care Patients |
- Lower Extremity Deep Venous Thrombosis
|
- Drug: heparin
- Drug: enoxaparin
|
Interventional |
Not Applicable |
- Lisa Louwers
- William Beaumont Hospitals
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Development of lower extremity deep venous thrombosis
- Adverse events associated with use of subcutaneous heparin and enoxaparin
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT01325779 |
HIC 2010-113 |
|
March 2011 |
February 2013 |
May 2013 |
March 30, 2011 |
May 20, 2013 |
|
- William Beaumont Hospital
Royal Oak, Michigan, United States
|
| 20 |
NCT01855100 |
Completed |
Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) |
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
|
Observational |
|
- Bayer
- Janssen Scientific Affairs, LLC
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients with major bleedings
- Number of patients with symptomatic recurrent Venous Thrombus Embolism (VTE)
- All-cause mortality
- (and 3 more...)
|
131 |
All |
18 Years and older (Adult, Senior) |
NCT01855100 |
16852
XA1314BE |
BOX-DVT |
July 2013 |
November 2014 |
December 2014 |
May 16, 2013 |
January 18, 2017 |
|
|
| 21 |
NCT02752984 |
Recruiting |
Study on the Incidence of Early Deep Vein Thrombosis After Peripherally Inserted Central Catheter Insertion |
|
|
Observational |
|
- IRCCS Policlinico S. Matteo
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Early Deep Vein Thrombosis incidence assessed with weekly ultrasound examination
- Factors which may be correlated to Deep Vein Thrombosis development: obesity (Body Mass Index)
- Factors which may be correlated to Deep Vein Thrombosis development: cancer
- (and 3 more...)
|
400 |
All |
Child, Adult, Senior |
NCT02752984 |
TROMBOSI VENOSA PROFONDA |
DVT-PICC |
April 2016 |
December 2017 |
June 2018 |
April 27, 2016 |
April 27, 2016 |
|
- IRCCS Policlinico San Matteo Pavia
Pavia, PV, Italy
|
| 22 |
NCT01285661 |
Completed |
Optimal Duration of Anticoagulation in Deep Venous Thrombosis |
- Deep Vein Thrombosis of Lower Limb
- Lower Extremity Deep Venous Thrombosis Recurrent
|
|
Interventional |
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrent venous thromboembolism (VTE)
- Development of major bleeding complications
|
584 |
All |
18 Years and older (Adult, Senior) |
NCT01285661 |
2001P |
MORGAGNI |
March 2010 |
October 2015 |
October 2015 |
January 28, 2011 |
July 19, 2016 |
|
- Paolo Prandoni
Padua, Italy
|
| 23 |
NCT02581176 |
Recruiting |
Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study |
- Neoplasms
- Venous Thrombosis
|
|
Interventional |
Phase 4 |
- University Hospital, Akershus
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrent objectively confirmed venous thrombosis or death related to venous thrombosis
- Major or clinically relevant non-major bleeding
- All cause mortality
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT02581176 |
CAP |
CAP |
April 2016 |
December 2018 |
January 2021 |
October 20, 2015 |
March 13, 2017 |
|
- Haukeland University Hospital
Bergen, Norway - Vestre Viken- Drammen Hospital
Drammen, Norway - Vestre Viken - Bærum sykehus
Gjettum, Norway - (and 7 more...)
|
| 24 |
NCT01412242 |
Completed |
Simplification of the Diagnosis of Deep Vein Thrombosis |
|
- Other: Extensive search for isolated calf DVT
|
Interventional |
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Safety of withdrawing anticoagulation from patients labeled as not having DVT on the basis of a one-day examination
- The rate of isolated calf vein thrombi
|
1100 |
All |
18 Years and older (Adult, Senior) |
NCT01412242 |
2188P |
PALLADIO |
March 2011 |
July 2014 |
September 2014 |
August 9, 2011 |
January 26, 2015 |
|
- Paolo Prandoni
Padua, Italy
|
| 25 |
NCT01779648 |
Completed
Has Results |
Comparison of Different Intermittent Pneumatic Compression Devices for Deep Vein Thrombosis |
- Venous Thrombosis
- Deep Vein Thrombosis
|
- Device: DVT-3000
- Device: SCD Express
|
Interventional |
Not Applicable |
- Seoul National University Hospital
- DS MAREF Co., Ltd.
- Small and Medium Business Administration, KOREA
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Rate of Deep Vein Thrombosis
- Peak Velocity
- Mean Velocity
- (and 9 more...)
|
54 |
All |
Child, Adult, Senior |
NCT01779648 |
IPCDVT |
|
March 2012 |
January 2013 |
January 2013 |
January 30, 2013 |
May 1, 2013 |
April 10, 2013 |
- SMG-SNU Boramae Medical Center
Seoul, Korea, Republic of
|
| 26 |
NCT02078154 |
Terminated |
Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis |
|
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- STA Liatest DDi results in DVT positive cases
- STA Liatest DDi Versus STA Liatest DDi Plus
|
6 |
All |
up to 80 Years (Child, Adult, Senior) |
NCT02078154 |
D-Dimer DVT |
|
April 2014 |
January 2015 |
January 2015 |
March 5, 2014 |
June 3, 2015 |
|
- The University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
|
| 27 |
NCT02486445 |
Recruiting |
Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study |
|
|
Interventional |
Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of serious bleedings and/or death related to bleeding
- Feasibility
- Failure rate
- 90-day outcome
|
825 |
All |
18 Years to 95 Years (Adult, Senior) |
NCT02486445 |
3304 |
Ri-Schedule |
March 2015 |
December 2018 |
June 2019 |
July 1, 2015 |
October 2, 2017 |
|
- Ostfold Hospital Trust
Fredrikstad, Ostfold, Norway
|
| 28 |
NCT02361294 |
Unknown † |
Immature Plateletes in the Etiopathology of Deep Venous Thrombosis |
- Immature Platelets
- Deep Venous Thrombosis
|
|
Observational |
|
- Technische Universität München
|
Other |
- Time Perspective: Prospective
|
- Significantly increased proportion of immature platelets in patients with deep venous thrombosis and/or pulmonary embolism compared to the control.
- Significantly higher values of platelet function in patients with deep venous thrombosis and/or pulmonary embolism compared to the control.
- A persistently increased proportion of immature platelets in patients with deep venous thrombosis and/or pulmonary embolism compared to the controls three months after diagnosis.
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02361294 |
TechnischeUM 1 |
iPLATELET |
December 2014 |
December 2015 |
March 2016 |
February 11, 2015 |
February 11, 2015 |
|
- Klinikum rechts der Isar, Technische Universität München
Munich, Germany
|
| 29 |
NCT00440193 |
Completed
Has Results |
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study |
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
- Drug: Enoxaparin followed by VKA
|
Interventional |
Phase 3 |
- Bayer
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
- Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment
- Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment
- (and 4 more...)
|
3449 |
All |
18 Years and older (Adult, Senior) |
NCT00440193 |
11702a
2006-004495-13
11702b |
|
March 2007 |
April 2010 |
April 2010 |
February 26, 2007 |
February 27, 2014 |
January 24, 2013 |
- Little Rock, Arkansas, United States
- Redlands, California, United States
- Bay Pines, Florida, United States
- (and 321 more...)
|
| 30 |
NCT03038893 |
Completed |
Point of Care Ultrasound For The Diagnosis Of Deep Venous Thrombosis And Its Effect On Length Of Hospital Stay |
- Deep Venous Thromboses
- Deep Venous Thrombosis of Left Leg
- Deep Venous Thrombosis of Right Leg
- Deep Venous Thrombosis Proximal
|
- Diagnostic Test: Point Of Care Ultrasound (PODUS)
- Diagnostic Test: Echo Doppler Ultrasound (EDUS)
|
Interventional |
Not Applicable |
- Hospital de Clinicas de Porto Alegre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Diagnostic
|
- Length of hospital stay
- Time to first diagnostic information
- Time to therapeutic decision making / prescription
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT03038893 |
54321516.0.0000.5327 |
|
August 1, 2016 |
November 30, 2016 |
January 30, 2017 |
February 1, 2017 |
February 1, 2017 |
|
|
| 31 |
NCT01670188 |
Terminated
Has Results |
SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines |
|
- Device: Pneumatic SCD - VenaFlow System (DJO Global)
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of Patients Who Experienced an Ultrasonographically-confirmed Venous Thrombosis
|
78 |
All |
18 Years and older (Adult, Senior) |
NCT01670188 |
12-004676 |
|
August 2012 |
October 13, 2016 |
October 13, 2016 |
August 22, 2012 |
January 9, 2018 |
January 9, 2018 |
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
| 32 |
NCT02697123 |
Active, not recruiting |
Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients |
- Venous Thrombosis
- Pregnancy
|
- Other: antepartum and postpartum
|
Observational |
|
- Baylor College of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- incidence of Venous Thrombosis in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication
|
5 |
Female |
18 Years to 64 Years (Adult) |
NCT02697123 |
H-36192 |
|
January 2016 |
January 2019 |
January 2019 |
March 3, 2016 |
February 1, 2018 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
| 33 |
NCT03483207 |
Not yet recruiting
New |
Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies |
- Mesenteric Vein Thrombosis
|
- Drug: Warfarin
- Procedure: MVT with failure of anticoagulation therapy
- Drug: Heparin
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Anticoagulation therapy (heparin &warfarin) in MVO
- Recurrence rate
- Mortality rate
|
30 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03483207 |
HF2018 |
|
April 1, 2018 |
December 2019 |
December 2019 |
March 30, 2018 |
March 30, 2018 |
|
|
| 34 |
NCT01662908 |
Completed
Has Results |
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis |
- Deep Vein Thrombosis
- Venous Thrombosis
|
- Drug: edoxaban tosylate
- Drug: enoxaparin/unfractionated heparin
- Drug: warfarin
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relative Change From Baseline in Thrombus Volume Assessed by MRI [Using the Magnetic Resonance Venography (MRV) Method]
- Number of Participants With Clinically Relevant Bleeding
- Number of Participants With Recurrence of Venous Thromboembolism (VTE)
- (and 2 more...)
|
85 |
All |
18 Years and older (Adult, Senior) |
NCT01662908 |
DU176b-D-U211 |
eTRIS |
August 2012 |
January 2014 |
March 2014 |
August 13, 2012 |
June 8, 2017 |
May 12, 2017 |
- Dothan, Alabama, United States
- Montgomery, Alabama, United States
- Sacramento, California, United States
- (and 31 more...)
|
| 35 |
NCT02867163 |
Recruiting |
Tranexamic Acid and Blood Clots in Knee Surgery |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02867163 |
TXA in TKR |
|
January 2017 |
November 2017 |
December 2018 |
August 15, 2016 |
February 19, 2018 |
|
- Sandoval Regional Medical Center
Rio Rancho, New Mexico, United States
|
| 36 |
NCT03157843 |
Recruiting |
Rate of Venous Thrombosis in Acutely Ill Patients Hospitalized in Internal Medicine Wards |
- Venous Thromboembolism
- Deep Venous Thrombosis
|
- Drug: low-molecular-weight heparin
|
Observational |
|
- University of Roma La Sapienza
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
|
1000 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03157843 |
AURELIO |
AURELIO |
February 2015 |
December 2017 |
January 2018 |
May 17, 2017 |
May 17, 2017 |
|
- Sapienza University of Rome
Rome, Italy
|
| 37 |
NCT02767232 |
Not yet recruiting |
Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial |
- Deep Vein Thrombosis
- Post-Thrombotic Syndrome
- Venous Thrombosis
|
- Drug: Recombinant tissue plasminogen activator (rt-PA)
- Drug: Standard Anticoagulation Therapy
|
Interventional |
Phase 3 |
- University of Colorado, Denver
- RTI International
- Mid America Heart Institute
- (and 2 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Development of Post-Thrombotic Syndrome (PTS)
- Change in Quality of Life (PedsQL)
- Change in Quality of Life (Peds-VEINES)
- (and 4 more...)
|
270 |
All |
6 Years to 21 Years (Child, Adult) |
NCT02767232 |
14-0659
ML29463 |
PHLO |
July 2018 |
April 2023 |
June 2023 |
May 10, 2016 |
September 20, 2017 |
|
|
| 38 |
NCT03286985 |
Recruiting |
The Prevalence and Incidence of DVT in General ICU |
|
|
Observational |
|
- Masaryk Hospital Krajská zdravotní a.s.
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of deep venous thrombosis
- Prevalence of deep venous thrombosis
|
200 |
All |
Child, Adult, Senior |
NCT03286985 |
236/60 |
preTIME |
April 1, 2017 |
February 2018 |
May 2018 |
September 19, 2017 |
September 19, 2017 |
|
- Masaryk Hospital
Ústí nad Labem, Česká Republika, Czechia
|
| 39 |
NCT02123524 |
Suspended |
Rivaroxaban Anticoagulation for Superficial Vein Thrombosis |
- Symptomatic Superficial Vein Thrombosis
|
- Drug: Rivaroxaban
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT02123524 |
OCOG-2013-RASET |
RASET |
November 11, 2014 |
December 2017 |
March 2018 |
April 25, 2014 |
December 20, 2017 |
|
- University of Alberta Hospital
Edmonton, Alberta, Canada - Hamilton General Hospital
Hamilton, Ontario, Canada - St Josephs Healthcare
Hamilton, Ontario, Canada - (and 8 more...)
|
| 40 |
NCT00539942 |
Terminated
Has Results |
Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy |
|
- Drug: Arixtra (fondaparinux sodium)
- Device: Intermittent compression devices (ICD)
|
Interventional |
Phase 3 |
- University of Alabama at Birmingham
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Comparison of Deep Venous Thromboembolism (DVT) Using Intermittent Compression Devices With and Without Arixtra
- Incidence of Untoward Effects With Arixtra
|
7 |
Female |
19 Years to 85 Years (Adult, Senior) |
NCT00539942 |
F070727009
UAB 0723 |
|
April 2007 |
June 2010 |
June 2010 |
October 5, 2007 |
March 27, 2017 |
March 9, 2012 |
- UAB, Women's and Infant Center, 1700 6th Avenue South
Birmingham, Alabama, United States
|
| 41 |
NCT00786422 |
Completed
Has Results |
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer |
- Venous Thrombosis
- Deep Vein Thrombosis
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
|
Interventional |
Phase 2 |
- Bayer
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacodynamics - Prothrombin Time (PT), Baseline Value
- Pharmacodynamics - Prothrombin Time (PT), Slope
- Pharmacokinetics - AUC(0-24)ss (Area Under the Measurement Versus Time Curve From Time 0 to 24 Hours After First Dosing on a Day at Steady State) of Rivaroxaban
- (and 7 more...)
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00786422 |
13238
2008-003303-31 |
|
May 2009 |
May 2011 |
June 2011 |
November 6, 2008 |
November 18, 2015 |
June 13, 2014 |
- Redcliffe, Queensland, Australia
- Wien, Austria
- São Paulo, Sao Paulo, Brazil
- (and 13 more...)
|
| 42 |
NCT00643201 |
Completed
Has Results |
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism |
|
- Drug: Enoxaparin
- Drug: warfarin
- Drug: Placebo for apixaban
- (and 3 more...)
|
Interventional |
Phase 3 |
- Bristol-Myers Squibb
- Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment
- Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death
- Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death
- (and 18 more...)
|
5614 |
All |
18 Years and older (Adult, Senior) |
NCT00643201 |
CV185-056
EUDRACT: 2007-007867-25 |
|
July 2008 |
March 2013 |
March 2013 |
March 26, 2008 |
April 21, 2014 |
April 10, 2014 |
- Alabama Clinical Therapeutics, Llc
Birmingham, Alabama, United States - Horizon Research Group, Inc.
Mobile, Alabama, United States - Fort Smith Lung Center
Fort Smith, Arkansas, United States - (and 379 more...)
|
| 43 |
NCT00633893 |
Completed
Has Results |
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism |
|
- Drug: Apixaban
- Drug: Placebo
|
Interventional |
Phase 3 |
- Bristol-Myers Squibb
- Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
- Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
- Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation
- (and 19 more...)
|
2711 |
All |
18 Years and older (Adult, Senior) |
NCT00633893 |
CV185-057
EUDRACT: 2007-004953-27 |
|
May 2008 |
August 2012 |
August 2012 |
March 12, 2008 |
November 25, 2013 |
October 25, 2013 |
- Alabama Clinical Therapeutics, Llc
Birmingham, Alabama, United States - Cardiovascular Consultants, Ltd.
Phoenix, Arizona, United States - Robert J. Bloomberg, Md, Pc
Tempe, Arizona, United States - (and 426 more...)
|
| 44 |
NCT02038530 |
Recruiting |
The Designer D-dimer Deep Vein Thrombosis Diagnosis (4D) Study |
- Suspected Deep Vein Thrombosis
|
|
Observational |
|
- McMaster University
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Confirmed symptomatic proximal Deep Vein Thrombosis
- Clinical Pretest Probability/ D-dimer/ Compression Ultrasound subgroups
- Death
|
1500 |
All |
18 Years and older (Adult, Senior) |
NCT02038530 |
OCOG-2013-4D |
4D |
February 2014 |
March 2018 |
March 2018 |
January 16, 2014 |
December 13, 2016 |
|
- University of Alberta Hospital
Edmonton, Alberta, Canada - Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada - Hamilton Health Sciences - Hamilton General
Hamilton, Ontario, Canada - (and 6 more...)
|
| 45 |
NCT01501175 |
Completed |
Incidence of Superficial Vein Thrombosis |
- Superficial Vein Thrombosis
|
- Other: consultation with a vascular physician
|
Observational |
|
- Centre Hospitalier Universitaire de Saint Etienne
- Ministry of Health, France
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- symptomatic SVT
- SVT risk factors
- SVT Clinical signs
|
848 |
All |
18 Years and older (Adult, Senior) |
NCT01501175 |
1108036
11.385 |
STEPH |
November 2011 |
November 2012 |
January 2013 |
December 29, 2011 |
February 13, 2013 |
|
- Cabinet D'Angiologie
Firminy, France - Ch Firminy
Firminy, France - Cabinet D'Angiologie
Saint Chamond, France - (and 5 more...)
|
| 46 |
NCT01029821 |
Unknown † |
Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis |
|
- Drug: Low-Molecular-Weight Heparin
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- We will compare the rates of thrombi formation between the two groups. We will record any clinical significant thrombi or complications that arise from thrombi. We will record any complications related to administration of LMWH.
- We may find that there is in fact significant benefit to giving prophylaxis to this subset of patients in the form of decreased rates of throb\mbus formation and the complications related to thrombi. The risk/benefit ratio should be favorable.
|
100 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01029821 |
Pugh-2 |
|
February 2010 |
December 2013 |
December 2013 |
December 10, 2009 |
June 16, 2011 |
|
- Erlanger Medical Center
Chattanooga,, Tennessee, United States
|
| 47 |
NCT00041782 |
Terminated |
Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients |
- Neoplasms
- Deep Vein Thrombosis
|
- Drug: Dalteparin (Fragmin)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Brookdale University Hospital Medical Center
- Josephine Ford Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Quality of Life Survey Responses
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT00041782 |
ID00-078 |
|
October 2000 |
January 2005 |
January 2005 |
July 19, 2002 |
July 31, 2012 |
|
- UT MD Anderson Cancer Center
Houston, Texas, United States
|
| 48 |
NCT02123550 |
Recruiting |
Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection |
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Sonographic evidence of a thrombosis
|
1000 |
All |
Child, Adult, Senior |
NCT02123550 |
Swanson01 |
|
January 2014 |
December 2014 |
December 2018 |
April 25, 2014 |
April 22, 2016 |
|
- Swanson Center
Leawood, Kansas, United States
|
| 49 |
NCT02368314 |
Completed
Has Results |
A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Frequency of DVT.
- Frequency of Symptomatic Nonlethal Thromboembolia of the Pulmonary Artery (PATE)
- Frequency of Venous Thromboembolism Death
- (and 15 more...)
|
124 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02368314 |
BCD-080-2 |
|
January 2015 |
December 2015 |
December 2015 |
February 23, 2015 |
October 24, 2016 |
October 24, 2016 |
- Railroad Clinical Hospital at the station Chelyabinsk
Chelyabinsk, Russian Federation
|
| 50 |
NCT01045759 |
Terminated |
Point of Care Ultrasound (US) Versus Detailed Radiology US for Deep Vein Thrombosis (DVT) |
|
|
Observational |
|
- University of Missouri-Columbia
|
Other |
- Time Perspective: Prospective
|
- The agreement between physician performed ultrasound and formal duplex ultrasonography for detection of proximal deep vein thrombosis.
- Subgroup analysis: location of thrombus (proximal or distal)
- Subgroup analysis: number of days in the hospital prior to exam
- (and 9 more...)
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT01045759 |
1143800 |
|
November 2009 |
May 2015 |
May 2015 |
January 11, 2010 |
September 30, 2016 |
|
- University of missouri healthcare
Columbia, Missouri, United States
|
Create an RSS feed from your search for:
Download the search results for: